Monash IVF Group Net Margin
The Net Profit Margin of Monash IVF Group (MVF.AX) as of Jul 25, 2026 is 9.20 %. In the previous year, Net Profit Margin was -2.56 % — a change of -459.25% (higher).
Get this data via API
Financial Data API
Net Margin
9.20 %
YoY
-459.25%
Last updated:
Net Profit Margin of Monash IVF Group is 2026 9.20 % . Net Profit Margin of Monash IVF Group was 2025 -2.56 % . It decreases by -459.25% higher compared to the previous year.
Monash IVF Group's net margin stands at 9.2%, down from 13.8% several years earlier.
Access this data via the Eulerpool API
Monash IVF Group Stock analysis
What does Monash IVF Group do? The Monash IVF Group Ltd is a company in Australia specializing in reproductive medicine. It was founded in 1970 by Professor Gab Kovacs, who is considered one of the pioneers in the field of in-vitro fertilization (IVF).
The company's history began in a small laboratory in Melbourne, where the first successful IVF procedures were performed. Over time, Monash IVF grew and expanded its focus to include other reproductive treatments such as donor egg programs, sperm donation, and cryopreservation.
Monash IVF Group Ltd has since become a leading provider in Australia, with 19 clinics throughout the country. The company is not only active in Australia but also operates clinics in Malaysia and Vietnam.
The business model of Monash IVF Group Ltd is centered around helping couples and individuals fulfill their desire to have children. The company offers a wide range of treatments tailored to the individual needs and circumstances of each patient.
Among the services offered are not only IVF, donor egg programs, and sperm donation but also other technologies such as intracytoplasmic sperm injection (ICSI) and preimplantation genetic diagnosis (PGD). Monash IVF Group Ltd sees itself as an all-rounder and therefore also offers psychological support and guidance during and after treatments.
One of the company's specialties is its comprehensive research work. The Monash IVF Group has a specialized research department actively involved in researching new reproductive technologies. The company collaborates closely with universities and leading scientific institutes to gain the latest insights in this field and achieve the best possible outcomes for its patients.
Monash IVF Group Ltd is divided into various divisions, each with different focuses and offerings. The main division is the Monash IVF Clinic, specializing in reproductive health and fertility. Here, all common IVF and fertility treatments are offered.
Another division is Monash IVF Fertility Diagnostics, specializing in diagnostics and screening of fertility and reproductive problems. State-of-the-art diagnostic procedures for evaluating male and female fertility are used here.
Monash IVF Genomics is another division offering genetic counseling, screening, and diagnostics. Here, couples can determine their genetic risk factors for fertility problems and receive support in making the best possible decisions regarding family planning.
In addition to these divisions, Monash IVF Group Ltd also offers specialized services. For example, there is the Monash IVF Donor Program, specializing in the facilitation of anonymous and open donor programs. The Monash IVF DNA Matching can also assist in the search for genetic relatives by utilizing advanced DNA profiling.
As a leading company in the field of fertility, Monash IVF Group Ltd offers a wide range of products and services to help couples and individuals fulfill their desire to have children. With a long history of innovation and research, as well as a variety of divisions and offerings, the company is an important provider of reproductive medicine in Australia and beyond. Monash IVF Group is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Monash IVF Group stock
Net Profit Margin of Monash IVF Group is 9.20 % in 2026.
Access this data via the Eulerpool API
Margins — Monash IVF Group
All Key Metrics — Monash IVF Group
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth